- Home
- WCT vs MEIP Comparison
WCT vs MEIP Comparison
Compare WCT & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- MEIP
- Stock Information
- Founded
- WCT 2012
- MEIP 2000
- Country
- WCT Hong Kong
- MEIP United States
- Employees
- WCT N/A
- MEIP N/A
- Industry
- WCT
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- WCT
- MEIP Health Care
- Exchange
- WCT NYSE
- MEIP Nasdaq
- Market Cap
- WCT 12.1M
- MEIP 13.3M
- IPO Year
- WCT 2024
- MEIP 2003
- Fundamental
- Price
- WCT $0.20
- MEIP $5.18
- Analyst Decision
- WCT
- MEIP Hold
- Analyst Count
- WCT 0
- MEIP 1
- Target Price
- WCT N/A
- MEIP N/A
- AVG Volume (30 Days)
- WCT 2.9M
- MEIP 3.0M
- Earning Date
- WCT 05-16-2025
- MEIP 09-18-2025
- Dividend Yield
- WCT N/A
- MEIP N/A
- EPS Growth
- WCT N/A
- MEIP N/A
- EPS
- WCT N/A
- MEIP N/A
- Revenue
- WCT $2,309,218.00
- MEIP N/A
- Revenue This Year
- WCT N/A
- MEIP N/A
- Revenue Next Year
- WCT N/A
- MEIP N/A
- P/E Ratio
- WCT N/A
- MEIP N/A
- Revenue Growth
- WCT N/A
- MEIP 33.76
- 52 Week Low
- WCT $0.12
- MEIP $1.46
- 52 Week High
- WCT $9.36
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- MEIP 58.66
- Support Level
- WCT N/A
- MEIP $4.87
- Resistance Level
- WCT N/A
- MEIP $6.88
- Average True Range (ATR)
- WCT 0.00
- MEIP 1.02
- MACD
- WCT 0.00
- MEIP -0.04
- Stochastic Oscillator
- WCT 0.00
- MEIP 39.94
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.